Skip to main content

Table 3 Plasma lipid concentrations in the control sample, grouped by LPL genotype.

From: The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion

   SS (n = 120) SX + XX (n = 41) p-value
Age   45.4 ± 18.69 (120) 50.8 ± 21.67 (41) 0.131
BMI   25.5 ± 4.38 (68) 25.0 ± 3.19 (25) 0.615
TG* Total 92.1 ± 36.66 (120) 87.9 ± 41.30 (41) 0.544
  VLDL 47.8 ± 30.01 (98) 47.3 ± 30.70 (35) 0.934
  LDL 31.0 ± 12.30 (98) 27.0 ± 11.37 (35) 0.099
  HDL 15.7 ± 4.83 (117) 14.8 ± 5.00 (41) 0.303
C* Total 184.8 ± 35.19 (120) 181.3 ± 41.01 (41) 0.654
  VLDL 11.3 ± 8.17 (98) 10.6 ± 6.59 (35) 0.796
  LDL 123.7 ± 27.00 (98) 117.5 ± 40.53 (35) 0.406
  HDL 52.6 ± 15.33 (117) 53.9 ± 10.34 (41) 0.553
TG/HDL-C 2.05 ± 1.51 (117) 1.75 ± 1.08 (41) 0.211
  1. *Lipid measurements expressed in mg/dL. Total cholesterol assessed by Wilcoxon two sample test.
  2. TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein – cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL, high density lipoprotein; BMI, body mass index; SS, individuals homozygous for the Ser447 allele; SX+XX, individuals that carry either one or two 447X alleles.